Therapeutic antibody development is one of the most promising areas of focus for the treatment of cancer, inflammatory and autoimmune diseases, and a broad spectrum of other medical conditions. Their high specificity and precise drug delivery are two unique attributes leading to their effectiveness towards difficult to treat diseases. However, this area of R&D is also one of the most challenging across all aspects of design, manufacturing, and formulation.

Antibody by Design

The antibody drug discovery process begins with screening, target identification, characterization, and validation. While significant advances have been made in high-throughput screening technologies for biopharmaceutical discovery, the future of antibody design relies on the ability to effectively utilize predictive models for multi-parameter target evaluation and optimization.

 A necessary prerequisite for successfully deploying advanced analytics is a fully digitized and connected laboratory environment. Digital transformation holds the promise for overall process improvement and better access to data, leading to substantial gains in R&D efficiency. The biopharmaceutical industry has historically taken a cautious approach to change, and therefore digital transformation, in part due to potential risk factors and compliance burdens. Recently, these efforts have been gaining momentum with the promise of accelerating scientific innovation, however, the complexities of digitally transforming the biopharmaceutical laboratory and lack of robust commercially available tools have created substantial roadblocks to progress.

A New Digital Paradigm

 Bionamic (Lund, Sweden) is changing the paradigm for antibody development. Founded by Dr. Anders Carlsson and Dr. Morten Krogh, whose combination of experiences from life science (Scripps Research and USC), theoretical physics (Princeton and CERN) and software development is fertile ground for creating the best therapeutic antibody research platform in the world.

 The idea behind Bionamic was developed while consulting at various biopharma companies, where the challenges of organizing and analyzing development data were obvious and researchers were frustrated by the inefficiencies caused by the lack of appropriate software. The central concept underpinning the Bionamic software platform is the integration of the multiple types of biopharmaceutical data within your laboratory ecosystem, including LIMS and ELN, to fully digitize your antibody discovery and development process.

Bioinformatics lies at the core of the development of biological therapeutics. Common but complex questions involving antibodies, their targets, history and performance can be answered through a network of biological relations that connect your data using Bionamic’s powerful search functionality.

Your antibody data is stored as an audit trail and every change is traceable to who, what, and when – including deletions. Once entered, your data is securely stored in the cloud and will always be available and recoverable.

Summary

 Bionamic’s cloud-hosted software platform (SaaS) is designed to trace, analyze and validate antibody sequence and assay data using key structures and relations based upon true biologic and physical concepts providing the digital continuity needed to modernize antibody development and eliminate the barriers to achieving digital transformation in biopharma R&D.

Why it Matters for You

The future of antibody design relies on the ability to effectively utilize predictive models for multi-parameter target evaluation and optimization, requiring digital continuity within the laboratory environment which can be a frustrating challenge within biopharma R&D. Bionamic is accelerating scientific innovation by changing the paradigm for the digitalization of antibody development in the following ways:

• Bionamic’s cloud-hosted software platform (SaaS) is designed to trace, analyze and validate antibody sequence and assay data using key structures and relations based upon true biologic and physical concepts.
• The Bionamic software platform integrates multiple types of biopharmaceutical data within your laboratory ecosystem, including full integration with LIMS and ELN, modernize antibody development and eliminate the barriers to achieving digital transformation in biopharma R&D.
• State-of-the-art data encryption and storage allows instant access and secure collaboration across multiple sites in a compliant framework.

About Astrix

For over 25 years, Astrix has been a market-leader in dedicated digital transformation & staffing services for science-based businesses. Through our proven laboratory informatics, digital quality & compliance, and scientific staffing services we deliver the highly specialized people, processes, and technology to fundamentally transform how science-based businesses operate. Astrix was founded by scientists to solve the unique challenges which science-based businesses face in the laboratory and beyond. We’re dedicated to helping our clients speed & improve scientific outcomes to help people everywhere.